Edwards Lifesciences (EW) Operating Expenses (2009 - 2026)

Edwards Lifesciences' Operating Expenses history runs 18 years deep, the most recent figure standing at $785.5 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 8.42% year-over-year to $785.5 million in Q1 2026; TTM through Mar 2026 was $3.5 billion, a 20.9% increase from a year earlier, with the FY2025 full-year figure at $3.5 billion, up 21.06% from the prior year.
• Operating Expenses retreated to $785.5 million in Q1 2026 per EW's latest filing, from $1.1 billion in the prior quarter.
• Across five years, Operating Expenses topped out at $1.1 billion in Q4 2025 and bottomed at $381.5 million in Q4 2022.
• The 5-year median for Operating Expenses is $719.3 million (2024), against an average of $720.5 million.
• Across the five-year window, Operating Expenses tumbled 42.54% in 2022 and soared 75.26% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $381.5 million in 2022, then surged by 75.26% to $668.6 million in 2023, then gained by 15.24% to $770.5 million in 2024, then surged by 40.06% to $1.1 billion in 2025, then decreased by 27.21% to $785.5 million in 2026.
• Per Business Quant, the three latest EW Operating Expenses figures stand at $785.5 million (Q1 2026), $1.1 billion (Q4 2025), and $885.7 million (Q3 2025).